Connect with us

Guides

Canopy Rivers’ Radicle Receives Approval for Production Facility Expansion from Health Canada

Stephen H

Published

on

Canopy Rivers' Radicle Receives Approval for Production Facility Expansion from Health Canada
  • Radicle Medical Marijuana Inc. is a subsidiary of Canopy Rivers.
  • The CEO of Canopy Rivers believes that the cannabis industry is going the same path of craft beer in their customer following.

Canopy Rivers, an investment and operating platform within the cannabis sector, is making some major progress in Canada. Their portfolio company – Radicle Medical Marijuana Inc. (or Radicle) – has now received approval from Health Canada to continue with its expansion project of their production facility. With this approval, the production footprint of Radicle could double, increasing the capacity to 6,000 kilograms annually, according to a press release with PR Newswire.

Narbe Alexandrian, the President and CEO of Canopy Rivers, expressed excitement over the “continued growth” of their company. Alexandrian added,

“The cannabis industry is showing many similarities to the craft beer movement, where local, artisanal operators are succeeding in securing loyal and robust customer followings. Radicle is thriving within this craft segment and is raising the bar when it comes to its unique strains offered under the Gage brand.”

Alexandrian commented that the company isn’t expanding demand from customers to go down. As the approval allows Radicle to supply more “high quality craft cannabis” that can be used in the medical and recreational markets.

The indoor facility of Radicle was originally licensed for cultivation last year, based on Ontario. The facility typically focuses on small-batch cultivation procedures with unique strains for the Gage cannabis brand. The approval allows Radicle to have a 40,000 square feet space for hydroponic cultivation.

Presently, Radicle is one of only two brands selected for adult-use sales online and in retail stores by the Ontario cannabis Store, following a product call that originally included 26 licensed cannabis producers. However, at the time they were selected, the company only had a cultivation license.

Canopy owns 22% of Radicle’s shares, following their first investment of Radicle in August 2017. As a result, Canopy Rivers already is entitled to receive royalty payments from the cannabis production of Radicle, securing a 20-year term to receive a minimum of $900,000 annually.

Stephen resides in Yorkshire, UK and is in his mid-fifties. Aside from a wide range of occupations, he was a National Health Service manager and psychiatric registered nurse before becoming a full time freelance writer. As a dedicated lifelong learner and rigid researcher, Stephen is keen to be one of our best contributors for year to come in the hemp and CBD industries.

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement

Join Us On Facebook

Advertisement

Trending CBD News

TimesofCBD always fact checks sources and aims for the best accuracy in the reporting curated cannabis content consisting of the latest CBD news, user guides and product health research. Quality is the priority, but we are not eligible to be liable as everything here is for educational, informational purposes only. Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.

What Is CBD?

Advertisement